Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
New and experimental HIV treatments
HIV Drug Aiming to Free Patients From Daily Doses Nears Market

A once-a-month shot promising to free patients from daily doses of treatment for HIV, the virus that causes AIDS, is expected to reach the market early next year after hitting goals in a pair of studies.

Published
08 March 2019
From
Bloomberg
The search for a cure
Using anti-cancer immunotherapy to fight HIV

Researchers at the University of Montreal Hospital Research Centre (CRCHUM) have shown that immunotherapy treatments against cancer could reduce the amount of virus that persists in people on triple therapy. In a study published in the journal Nature Communications, they show, in the cells of people living with HIV, how these therapies reveal the virus - until now hidden in the hollows of infected cells - to the immune system.

Published
20 February 2019
From
Eurekalert Medicine & Health
New and experimental HIV treatments
CytoDyn wins key concession from FDA for flagship HIV drug leronlimab trial

The FDA is allowing CytoDyn to increase the dose of the HIV drug leronlimab which patients in its clinical trial are receiving.

Published
04 February 2019
From
Proactive Investors USA & Canada
Long-acting HIV treatment
Emerging options: Doctors and advocates discuss treatment and prevention breakthroughs on the horizon

Long-acting injectables, implantables, the dapivirine ring, vaccines, antibodies, rectal douches, and two-drug regimens.

Published
30 January 2019
From
Positively Aware
New and experimental HIV treatments
South Africa: New safety concerns emerge on latest HIV wonder drug

New safety concerns have emerged about the HIV drug dolutegravir, which the government plans to roll out in April.

Published
18 January 2019
From
Business Day
New and experimental HIV treatments
Dolutegravir monotherapy 'not a valid option' for patients with HIV

Study results showed that dolutegravir monotherapy “is not a valid option” to keep patients with chronic HIV infection virologically suppressed and should not be considered a treatment option, researchers said.

Published
15 January 2019
From
Healio
Low CD4 count
‘Left behind’: Drug companies and researchers have overlooked patients who don’t respond to HIV meds

There are tens of thousands of immunologic non-responders in the U.S., whose low CD4 numbers put them at much higher risk of heart attacks, stroke, cancers, secondary infections such as tuberculosis, and death. And yet, drug companies and researchers aren’t actively pursuing new treatments that would boost their immunity.

Published
08 January 2019
From
STAT
Pharmaceutical industry
Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment

GlaxoSmithKline subsidiary ViiV Healthcare believes its portfolio of HIV medications will be competitive as treatment for the virus enters an era of two-drug regimens. So far, however, the company's first doublet has performed modestly on the market compared to a key rival's three-drug regimen.

Published
12 December 2018
From
BioPharma Dive
New and experimental HIV treatments
European Commission Approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine)

Merck, known as MSD outside the United States and Canada, today announced that the European Commission has approved DELSTRIGO™ and PIFELTRO™ for the treatment of HIV-1 infection. DELSTRIGO is a new once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg).

Published
28 November 2018
From
Merch press release
New and experimental HIV treatments
Tivicay Plus Boosted Prezista Shows Promise as Two-Drug HIV Regimen

However, the regimen appears much less potent for those who aren’t virally suppressed.

Published
16 November 2018
From
Poz
← Prev12345...58Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.